A detailed history of Macquarie Group LTD transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 1,014,689 shares of ADMA stock, worth $18.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,014,689
Previous 1,138,323 10.86%
Holding current value
$18.7 Million
Previous $22.8 Million 23.53%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$15.62 - $22.62 $1.93 Million - $2.8 Million
-123,634 Reduced 10.86%
1,014,689 $17.4 Million
Q3 2024

Nov 14, 2024

BUY
$11.21 - $20.03 $10.7 Million - $19.1 Million
955,990 Added 524.31%
1,138,323 $22.8 Million
Q2 2024

Aug 09, 2024

SELL
$5.98 - $11.18 $396,360 - $741,021
-66,281 Reduced 26.66%
182,333 $2.04 Million
Q1 2024

May 14, 2024

SELL
$4.4 - $6.74 $112,736 - $172,692
-25,622 Reduced 9.34%
248,614 $1.64 Million
Q4 2023

Feb 14, 2024

BUY
$3.08 - $4.52 $844,646 - $1.24 Million
274,236 New
274,236 $1.24 Million

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.62B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.